Gclc — Glutamate Cysteine Ligase Catalytic Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| GCLC — Glutamate-Cysteine Ligase Catalytic Subunit | |
|---|---|
| Symbol | GCLC |
| Full Name | Glutamate-Cysteine Ligase Catalytic Subunit |
| Chromosome | 6p12.3 |
| NCBI Gene | 2729 |
| Ensembl | ENSG00000001036 |
| OMIM | 606483 |
| UniProt | P48506 |
| Diseases | Parkinson's Disease, Alzheimer's Disease, Oxidative Stress |
| Expression | Liver, Kidney, Brain, Testis |
GCLC (Glutamate-Cysteine Ligase Catalytic Subunit) is a gene located on chromosome 6p12.3 that encodes the catalytic subunit of glutamate-cysteine ligase (GCL), the rate-limiting enzyme in glutathione biosynthesis. GCLC contains the active site of the enzyme and can form a functional enzyme when combined with GCLM (modifier subunit).
GCLC catalyzes the ATP-dependent formation of γ-glutamylcysteine from glutamate and cysteine, the first and rate-limiting step in glutathione synthesis. This reaction:
GCLC is essential for maintaining cellular redox homeostasis and protecting against oxidative damage in all tissues, including the brain.
Parkinson's Disease: GCLC expression and activity are reduced in the substantia nigra of PD patients, contributing to oxidative stress and dopaminergic neuron loss.
Alzheimer's Disease: GCLC dysfunction may contribute to amyloid-beta toxicity and oxidative damage in AD brains.
ALS: Altered GCLC expression has been reported in spinal cord tissue from ALS patients.
The study of Gclc — Glutamate Cysteine Ligase Catalytic Subunit has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.